SPRO RSI Chart
Last 7 days
-3.7%
Last 30 days
5.3%
Last 90 days
3.3%
Trailing 12 Months
-12.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 111.0M | 0 | 0 | 0 |
2023 | 53.5M | 54.2M | 77.7M | 103.8M |
2022 | 13.0M | 9.9M | 8.8M | 53.5M |
2021 | 14.9M | 18.4M | 17.4M | 18.3M |
2020 | 12.1M | 11.7M | 11.1M | 9.3M |
2019 | 10.5M | 12.2M | 16.2M | 18.1M |
2018 | 3.0M | 3.2M | 3.3M | 4.0M |
2017 | 663.7K | 992.3K | 1.3M | 2.0M |
2016 | 0 | 0 | 0 | 335.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 05, 2024 | shukla sath | sold | -65,384 | 1.45 | -45,093 | ceo and president |
Feb 02, 2024 | shukla sath | sold | -42,334 | 1.37 | -30,901 | ceo and president |
Feb 02, 2024 | joseph tamara l | sold | -42,341 | 1.37 | -30,906 | chief legal officer |
Feb 02, 2024 | hamed kamal | sold | -38,462 | 1.37 | -28,075 | chief medical officer |
Feb 02, 2024 | mahadevia ankit | sold | -87,399 | 1.37 | -63,795 | - |
Feb 02, 2024 | keutzer timothy | sold | -42,120 | 1.36 | -30,971 | chief operating officer |
Feb 01, 2024 | hamed kamal | acquired | - | - | 239,731 | chief medical officer |
Feb 01, 2024 | rajavelu esther | acquired | - | - | 119,866 | see remarks |
Feb 01, 2024 | joseph tamara l | acquired | - | - | 239,731 | chief legal officer |
Feb 01, 2024 | keutzer timothy | acquired | - | - | 239,731 | chief operating officer |
Which funds bought or sold SPRO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Murchinson Ltd. | added | 1.3 | 234,956 | 1,503,120 | 0.13% |
May 16, 2024 | AWM Investment Company, Inc. | unchanged | - | 83,350 | 573,448 | 0.07% |
May 15, 2024 | Man Group plc | new | - | 368,125 | 368,125 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 32,628 | 224,479 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -34.37 | -4,105 | 13,586 | -% |
May 15, 2024 | AMERIPRISE FINANCIAL INC | sold off | -100 | -592,356 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -9.7 | 478 | 8,930 | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 104 | 104 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | reduced | -13.19 | 24,783 | 1,594,320 | 0.36% |
May 15, 2024 | Shay Capital LLC | new | - | 527,983 | 527,983 | 0.08% |
Unveiling Spero Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Spero Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Spero Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -87.4% | 9,267,000 | 73,522,500 | 25,473,000 | 2,716,000 | 2,069,000 | 47,441,000 | 2,006,000 | 1,993,000 | 2,069,000 | 2,744,000 | 3,064,000 | 5,148,000 | 7,300,000 | 1,907,000 | 3,995,000 | 1,727,000 | 1,701,000 | 3,630,000 | 4,643,000 | 2,156,000 | 7,718,000 |
Operating Expenses | 1.1% | 23,249,000 | 22,990,500 | 27,407,000 | 15,606,000 | 16,296,000 | 21,517,000 | 13,840,000 | 28,073,000 | 32,276,000 | 30,246,000 | 25,588,000 | 23,690,000 | 26,703,000 | 20,703,000 | 23,015,000 | 20,203,000 | 24,522,000 | 29,513,000 | 22,628,000 | 15,808,000 | 13,414,000 |
S&GA Expenses | -100.0% | - | 6,433,000 | 5,708,000 | 6,096,000 | 7,317,000 | 6,495,000 | 6,632,000 | 8,051,000 | 15,305,000 | 13,021,000 | 11,152,000 | 9,229,000 | 8,299,000 | 7,498,000 | 5,309,000 | 4,547,000 | 4,086,000 | 3,785,000 | 4,133,000 | 3,782,000 | 3,888,000 |
R&D Expenses | 4.7% | 17,332,000 | 16,557,500 | 16,393,000 | 9,510,000 | 8,979,000 | 15,089,000 | 7,360,000 | 8,173,000 | 16,971,000 | 17,225,000 | 14,436,000 | 14,461,000 | 18,404,000 | 13,205,000 | 17,706,000 | 15,656,000 | 20,436,000 | 25,728,000 | 18,495,000 | 12,026,000 | 9,526,000 |
EBITDA Margin | - | - | - | - | - | - | - | - | -9.02 | -6.84 | -4.88 | - | - | -5.19 | -8.30 | -5.47 | -5.14 | -4.96 | -3.31 | -2.51 | -3.36 | -3.91 |
Income Taxes | -100.0% | - | 387,000 | 2,200,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | - | - | - | - | - | - | - | - | -9.09 | -6.89 | -4.92 | - | - | -5.24 | -8.39 | -5.51 | -5.21 | -5.02 | -3.36 | -2.57 | -3.41 | -3.96 |
Net Income | -124.7% | -12,669,000 | 51,191,000 | -3,205,000 | -11,914,000 | -13,266,000 | 26,771,000 | -11,675,000 | -28,682,000 | -32,829,000 | -29,240,000 | -22,521,000 | -18,572,000 | -19,423,000 | -18,585,000 | -18,936,000 | -17,501,000 | -23,258,000 | -24,986,000 | -17,717,000 | -13,150,000 | -5,072,000 |
Net Income Margin | -4.0% | 0.21 | 0.22 | -0.02 | -0.19 | -0.50 | -0.87 | -11.62 | -11.48 | -7.92 | -4.92 | -4.54 | -4.12 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 133.9% | 5,938,000 | -17,493,000 | 15,915,000 | -18,564,000 | -12,853,000 | 44,482,000 | -957,000 | -23,033,000 | -28,223,000 | -27,349,000 | -4,952,000 | -16,579,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -8.1% | 168 | 182 | 107 | 99.00 | 113 | 125 | 64.00 | 64.00 | 146 | 171 | 145 | 120 | 143 | 153 | 157 | 98.00 | 110 | 106 | 113 | 122 | 125 |
Current Assets | 6.8% | 140 | 131 | 102 | 88.00 | 102 | 114 | 53.00 | 52.00 | 133 | 158 | 132 | 106 | 129 | 139 | 143 | 85.00 | 98.00 | 95.00 | 104 | 113 | 116 |
Cash Equivalents | 7.8% | 82.00 | 76.00 | 94.00 | 78.00 | 96.00 | 109 | 50.00 | 45.00 | 72.00 | 113 | 113 | 72.00 | 77.00 | 85.00 | 125 | 65.00 | 64.00 | 30.00 | 46.00 | 71.00 | 49.00 |
Net PPE | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 |
Liabilities | -5.4% | 71.00 | 75.00 | 53.00 | 44.00 | 48.00 | 49.00 | 32.00 | 28.00 | 83.00 | 83.00 | 33.00 | 29.00 | 25.00 | 21.00 | 24.00 | 24.00 | 27.00 | 32.00 | 19.00 | 13.00 | 11.00 |
Current Liabilities | 12.6% | 42.00 | 37.00 | 25.00 | 17.00 | 23.00 | 22.00 | 16.00 | 14.00 | 69.00 | 19.00 | 17.00 | 13.00 | 18.00 | 14.00 | 18.00 | 19.00 | 23.00 | 27.00 | 15.00 | 8.00 | 7.00 |
Shareholder's Equity | -10.0% | 96.00 | 107 | 54.00 | 55.00 | 65.00 | 76.00 | 32.00 | 36.00 | 62.00 | 88.00 | 112 | 90.00 | 119 | 132 | 133 | 74.00 | 82.00 | 75.00 | 93.00 | 110 | 113 |
Retained Earnings | -3.2% | -403 | -391 | -442 | -439 | -427 | -413 | -440 | -428 | -400 | -367 | -338 | -315 | -297 | -277 | -259 | -240 | -222 | -199 | -174 | -156 | -143 |
Additional Paid-In Capital | 0.4% | 500 | 498 | 496 | 494 | 492 | 490 | 473 | 465 | 463 | 456 | 450 | 406 | 416 | 410 | 392 | 314 | 305 | 274 | 267 | 266 | 257 |
Shares Outstanding | 1.6% | 54.00 | 53.00 | 53.00 | 53.00 | 53.00 | 52.00 | 36.00 | 33.00 | 33.00 | 32.00 | 30.00 | 30.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
Float | - | - | - | - | 76.00 | - | 22.00 | - | - | - | - | - | 326 | - | - | - | 256 | - | - | - | 151 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 133.9% | 5,938 | -17,493 | 15,915 | -18,564 | -12,853 | 44,482 | -957 | -23,033 | -28,223 | -27,349 | -4,952 | -16,567 | -15,479 | -16,383 | -21,264 | -24,896 | -23,329 | -17,367 | -9,659 | -12,070 | -10,924 |
Share Based Compensation | 1.3% | 2,023 | 1,997 | 1,908 | 1,857 | 2,170 | 2,497 | 2,106 | 1,317 | 3,203 | 2,928 | 2,330 | 2,163 | 2,009 | 1,365 | 1,199 | 1,214 | 1,110 | 929 | 981 | 933 | 933 |
Cashflow From Investing | - | - | - | - | - | - | - | -129 | 50,000 | -16,064 | -23,275 | 17,025 | 10,919 | 3,003 | -39,740 | 3,949 | 18,485 | 27,776 | -4,099 | -15,887 | 24,845 | 24,671 |
Cashflow From Financing | -100.0% | - | 1.00 | 220 | - | - | 14,179 | 6,131 | -53,677 | 3,814 | 50,349 | 29,224 | 168 | 4,309 | 16,090 | 77,215 | 7,390 | 30,186 | 5,599 | 10.00 | 8,963 | 1,568 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Grant revenue | $ 5,063 | $ 1,329 |
Collaboration revenue - related party | 4,064 | 517 |
Collaboration revenue | $ 140 | $ 223 |
Type of Revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember |
Total revenues | $ 9,267 | $ 2,069 |
Operating expenses: | ||
Research and development | 17,332 | 8,979 |
General and administrative | 5,917 | 7,317 |
Total operating expenses | 23,249 | 16,296 |
Loss from operations | (13,982) | (14,227) |
Other income (expense): | ||
Interest income | 1,327 | 963 |
Other income (expense), net | (14) | (2) |
Total other income (expense), net | 1,313 | 961 |
Net loss and comprehensive loss | $ (12,669) | $ (13,266) |
Net loss per share attributable to common stockholders, basic | $ (0.24) | $ (0.25) |
Net loss per share attributable to common stockholders, diluted | $ (0.24) | $ (0.25) |
Weighted average common shares outstanding, basic | 53,524,037 | 52,527,018 |
Weighted average common shares outstanding, diluted | 53,524,037 | 52,527,018 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 82,271 | $ 76,333 |
Collaboration receivable, current - related party | 49,198 | 49,152 |
Other receivables | 5,017 | 1,545 |
Prepaid expenses and other current assets | 3,668 | 4,178 |
Total current assets | 140,154 | 131,208 |
Property and equipment, net | 2 | 2 |
Operating lease right of use assets | 3,902 | 4,155 |
Collaboration receivable, non-current - related party | 23,211 | 46,590 |
Other assets | 434 | 435 |
Total assets | 167,703 | 182,390 |
Current liabilities: | ||
Accounts payable | 3,066 | 1,378 |
Accrued expenses and other current liabilities | 5,380 | 6,557 |
Operating lease liabilities | 1,725 | 1,718 |
Income taxes payable | 387 | 387 |
Deferred revenue, current | 2,868 | 2,132 |
Deferred revenue, current - related party | 28,395 | 24,981 |
Total current liabilities | 41,821 | 37,153 |
Non-current operating lease liabilities | 3,519 | 3,825 |
Deferred revenue, non-current | 9,948 | 10,825 |
Deferred revenue, non-current - related party | 16,128 | 23,606 |
Other long-term liabilities | 38 | 87 |
Total liabilities | 71,454 | 75,496 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 53,869,139 shares issued and outstanding as of March 31, 2024 and 52,999,680 shares issued and outstanding as of December 31, 2023 | 54 | 53 |
Additional paid-in capital | 499,936 | 497,913 |
Accumulated deficit | (403,741) | (391,072) |
Total stockholders' equity | 96,249 | 106,894 |
Total liabilities and stockholders' equity | $ 167,703 | $ 182,390 |